<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34033974</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1556-1380</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title>
          <ISOAbbreviation>J Thorac Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).</ArticleTitle>
        <Pagination>
          <StartPage>1533</StartPage>
          <EndPage>1546</EndPage>
          <MedlinePgn>1533-1546</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2021.05.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1556-0864(21)02177-8</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION">Blocking vascular endothelial growth factor pathway can enhance the efficacy of EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study conducted in the People's Republic of China evaluating apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, plus gefitinib as first-line therapy in EGFR-mutant NSCLC.</AbstractText>
          <AbstractText Label="METHODS">Treatment-naive patients with stage IIIB or IV nonsquamous NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and EGFR exon 19 deletion or exon 21 L858R mutation were randomized 1:1 to receive oral gefitinib (250 mg/d), plus apatinib (500 mg/d; apatinib [A] + gefitinib [G] group), or placebo (placebo [P] + gefitinib [G] group). Stratification factors were mutation type, sex, and performance status. The primary end point was progression-free survival (PFS) by blinded independent radiology review committee (IRRC). Secondary end points were investigator-assessed PFS, overall survival, quality of life (QoL), safety, etc. Next-generation sequencing was used to explore efficacy predictors and acquired resistance.</AbstractText>
          <AbstractText Label="RESULTS">A total of 313 patients were assigned to the A + G (n = 157) or P + G group (n = 156). Median IRRC PFS in the A + G group was 13.7 months versus 10.2 months in the P + G group (hazard ratio 0.71, p = 0.0189). Investigator- and IRRC-assessed PFS were similar. Overall survival was immature. The most common treatment-emergent adverse events greater than or equal to grade 3 were hypertension (46.5%) and proteinuria (17.8%) in the A + G group and increased alanine aminotransferase (10.4%) and aspartate aminotransferase (3.2%) in the P + G group. QoL in the two groups had no statistical differences. Post hoc analysis revealed PFS benefits tended to favor the A + G group in patients with TP53 exon 8 mutation.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Apatinib + gefitinib as first-line therapy had superior PFS in advanced EGFR-mutant NSCLC versus placebo + gefitinib. Combination therapy brought more adverse events but did not interfere QoL.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION">NCT02824458.</AbstractText>
          <CopyrightInformation>Copyright © 2021. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Hongyun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Wenxiu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Oncology, Sichuan Cancer Hospital, Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Min</LastName>
            <ForeName>Xuhong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Radiotherapy, Anhui Chest Hospital, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Kangsheng</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Guohua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Weifang People's Hospital, Weifang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhonghan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Jiuwei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Department of Oncology Center, First Hospital of Jilin University, Changchun, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miao</LastName>
            <ForeName>Liyun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Xia</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Huizhou Municipal Central Hospital, Huizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Xiuhua</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Chengping</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Xiaoli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Qitao</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Ou</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Oncology, Neijiang Second People's Hospital, Neijiang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Xiuping</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jiwei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory, Nanjing First Hospital, Nanjing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Zhiguo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Quanren</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Rongrong</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xianfeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. Electronic address: zhangli@sysucc.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02824458</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Thorac Oncol</MedlineTA>
        <NlmUniqueID>101274235</NlmUniqueID>
        <ISSNLinking>1556-0864</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S371K6132</RegistryNumber>
          <NameOfSubstance UI="C553458">apatinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Thorac Oncol. 2021 Sep;16(9):1426-1428</RefSource>
          <PMID Version="1">34425993</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Thorac Oncol. 2021 Sep;16(9):e71-e72</RefSource>
          <PMID Version="1">34426001</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Thorac Oncol. 2021 Sep;16(9):e72-e76</RefSource>
          <PMID Version="1">34426002</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Thorac Oncol. 2021 Oct;16(10):e86-e87</RefSource>
          <PMID Version="1">34561043</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Thorac Oncol. 2021 Oct;16(10):e87-e88</RefSource>
          <PMID Version="1">34561044</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Apatinib</Keyword>
        <Keyword MajorTopicYN="Y">Epidermal growth factor receptor</Keyword>
        <Keyword MajorTopicYN="Y">Non–small cell lung cancer</Keyword>
        <Keyword MajorTopicYN="Y">Targeted therapy</Keyword>
        <Keyword MajorTopicYN="Y">Vascular endothelial growth factor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34033974</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jtho.2021.05.006</ArticleId>
        <ArticleId IdType="pii">S1556-0864(21)02177-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
